Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PDE6D | O43924 | 1/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30725358 | 1.00 | MAPT (0.46) | MAPTKDM4EMEN1USP2IDO1 | |
| SCHEMBL13587967 | 0.81 | LMNA (0.57) | KDM4EHTTALDH1A1PDE6DHRH1 | |
| SCHEMBL22128333 | 0.81 | POLB (0.44) | MAPTKDM4EHTTALDH1A1ATM | |
| SCHEMBL22128335 | 0.81 | POLB (0.44) | MAPTKDM4EHTTALDH1A1ATM | |
| SCHEMBL18404171 | 0.80 | KDM4E (0.48) | MAPTKDM4EMEN1HTTKMT2A | |
| SCHEMBL26979174 | 0.79 | KMT2A (0.56) | MAPTKDM4EMEN1HTTKMT2A | |
| SCHEMBL18496285 | 0.78 | BRD4 (0.60) | MAPTMEN1USP2HTTKMT2A | |
| SCHEMBL29719369 | 0.78 | BRD4 (0.60) | MAPTMEN1USP2HTTKMT2A | |
| SCHEMBL25679737 | 0.77 | KDM4E (0.57) | MAPTKDM4EMEN1USP2IDO1 | |
| SCHEMBL22152198 | 0.77 | TSHR (0.48) | MAPTMEN1HTTKMT2AGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2024-01-04 | — | — | US | disclosed |
| WO-2023250156-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002391-A1 | 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK2, DYRK1B | MAPT 402/4885KDM4E 1400/4885MEN1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.